Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease

Journal of Neurology Neurosurgery and Psychiatry

Volumn 74, Issue 5, 2003, Pages 574-576

  Sato, Y ^a,b   Asoh, T ^b   Metoki, N ^a   Satoh, K ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Futase Social Insurance Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DANTROLENE; LEVODOPA; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSCIOUSNESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HUMAN; HYPERTHERMIA; MALE; MENTAL DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGIDITY; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHYLPREDNISOLONE; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PULSE THERAPY, DRUG; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037962818     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.74.5.574     Document Type: Article

References (11)

1. Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology 1981;21:132-7.
2. Sechi GP, Tanda F, Mutani R. Fatal hyperpyrexia after withdrawal of levodopa. Neurology 1981;24:245-51.
3. Gibb WRG, Griffith DNW. Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome. Postgrad Med J 1986;62:59-60.
4. Nisijima K, Noguchi M, Ishiguro T. Intravenous injection of levodopa is more effective than dantrolene as therapy for neuroleptic malignant syndrome. Biol Psychiatry 1997;41:913-14.
5. Rossenberg MR, Green M. Neuroleptic malignant syndrome: review of response to therapy. Arch Intern Med 1989;149:1927-31.
6. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q 2001;72:25-36.
7. Tsujimoto S, Maeda K, Sugiyama T, et al. Efficacy of prolonged large-dose dantrolene for severe neuroleptic malignant syndrome. Anesth Analg 1998;86:1143-4.
8. Tsutsumi Y, Yamamoto K, Matsuyama S, et al. The treatment of neuroleptic malignant syndrome using dantrolene sodium. Psychiatry Clin Neurosci 1998;52:433-8.
9. Sakkas P, Davis JM, Hua J, et al. Pharmacotherapy of neuroleptic malignant syndrome. Psych Annals 1991;21:157-64.
10. Czyrak A, Chocyk A. Search for the presence of glucocorticoid receptors in dopaminergic neurons of rat ventral tegmental area and substantia nigra. Pol J Pharmacol 2001;53:681-94.
11. Piazza PV, Rouge-Pont F, Deroche V, et al. Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission. Proc Natl Acad Sci U S A 1996;93:8716-20.